Gilead Sciences Inc (GILD)

Mar 28, 2025

Gilead Sciences (NasdaqGS:GILD) Faces Shareholder Proposals As Stock Rises 5% - Simply Wall St

Mar 28, 2025

Mar 28, 2025

Gilead Prioritizes Women With Its First HIV Cure Trial In Africa - Clinical Leader

Mar 28, 2025

Mar 28, 2025

Another big payday for O'Day as Gilead boosts his compensation 5% to $23.7M - FiercePharma

Mar 28, 2025

Mar 28, 2025

Gilead to Boost China R&D to Make Access to Antiviral Drugs Faster, Country GM Says - Yicai Global

Mar 28, 2025

Mar 27, 2025

Gilead Sciences CEO's pay climbed to $23.7 million - The Business Journals

Mar 27, 2025

Mar 27, 2025

Gilead Says CEO Daniel O'Day's 2024 Total Compensation Was $23.7 MillionSEC Filing - Marketscreener.com

Mar 27, 2025

Mar 27, 2025

What Analysts Are Saying About Gilead Sciences Stock - Benzinga

Mar 27, 2025

Mar 27, 2025

A Closer Look at Gilead Sciences's Options Market Dynamics - Benzinga

Mar 27, 2025

Mar 27, 2025

J.P. Morgan Sticks to Their Buy Rating for Gilead Sciences (GILD) - The Globe and Mail

Mar 27, 2025

Mar 27, 2025

JPMorgan Adjusts Price Target on Gilead Sciences to $130 From $120, Maintains Overweight Rating - Marketscreener.com

Mar 27, 2025

Mar 26, 2025

Potential federal budget cuts won't rock Gilead's HIV boat too much: analysts - FiercePharma

Mar 26, 2025

Mar 26, 2025

Gilead’s HIV Treatments Could Face Headwinds. Why the Stock Will Still Rise. - Barron's

Mar 26, 2025

Mar 26, 2025

Gilead Sciences: Using Lessons From the HIV Epidemic To Help Reduce Stigma Around Lung Cancer - CSRwire.com

Mar 26, 2025

Mar 26, 2025

Are Medical Stocks Lagging Gilead Sciences (GILD) This Year? - Yahoo Finance

Mar 26, 2025

Mar 26, 2025

Gilead price tries to regain footingForecast today26-03-2025 - Economies.com

Mar 26, 2025

Mar 25, 2025

Former Gilead Sciences VP Named CEO as Biomea Advances Breakthrough Diabetes Drug - StockTitan

Mar 25, 2025

Mar 25, 2025

Gilead, J&J Sue Laurus Labs to Block Copy of HIV Drug Complera - Bloomberg Law

Mar 25, 2025

Mar 24, 2025

Gilead Sciences (GILD) Stock Drops Despite Market Gains: Important Facts to Note - Yahoo Finance

Mar 24, 2025

Mar 24, 2025

The Inner Circle acknowledges, Christopher McCormick as a Pinnacle Professional Member Inner Circle of Excellence - Yahoo Finance

Mar 24, 2025

Mar 24, 2025

Gilead Sees Success With HIV PrEP Trial In South Africa - Clinical Leader

Mar 24, 2025

Mar 23, 2025

Gilead: Expansion Of Livdelzi For PBC Continues With European Marketing Approval - Seeking Alpha

Mar 23, 2025

Mar 22, 2025

Gilead Sciences Inc (GILD) Shares Up 1.14% on Mar 22 - GuruFocus.com

Mar 22, 2025

Mar 21, 2025

Insider Sell: Andrew Dickinson Sells Shares of Gilead Sciences Inc (GILD) - GuruFocus.com

Mar 21, 2025

Mar 21, 2025

Pharmaceutical Firms Say UK Investment Is 'Unlikely' Unless Payment Levy Is Adressed - Benzinga

Mar 21, 2025

Mar 21, 2025

Gilead Sciences Inc (GILD) Stock Price Up 0.52% on Mar 21 - GuruFocus.com

Mar 21, 2025

Mar 21, 2025

Gilead Sciences stock performance analysis: A rare Nasdaq gem with consistent returns across time horizons - The Financial Express

Mar 21, 2025

Mar 21, 2025

The Zacks Analyst Blog Highlights Sarepta Therapeutics, Incyte, Gilead Sciences and VTv Therapeutics - Nasdaq

Mar 21, 2025

Mar 20, 2025

Gilead Sciences (GILD) Suffers a Larger Drop Than the General Market: Key Insights - Yahoo Finance

Mar 20, 2025

Mar 20, 2025

GILD Stock Down on Report of Cut in HIV Prevention Spending - Yahoo Finance

Mar 20, 2025

Mar 20, 2025

Oppenheimer doesn’t see threat to Gilead estimates after HHS plans for HIV cuts - Yahoo Finance

Mar 20, 2025

Mar 20, 2025

Gilead Stock Wobbles On Federal HIV Funding Cut Buzz, But Retail And Analysts Stay Unfazed - MSN

Mar 20, 2025

Mar 19, 2025

Trump Administration Weighs Deep Cuts To Domestic HIV Prevention Programs, Gilead Stock Slides - Yahoo Finance

Mar 19, 2025

Mar 19, 2025

Gilead Stock Falls on Report U.S. Could Slash HIV-Prevention Budget - The Wall Street Journal

Mar 19, 2025

Mar 19, 2025

Gilead stock falls on report of HIV prevention cuts - Yahoo Finance

Mar 19, 2025

Mar 19, 2025

Gilead Stock Dives On A Devastating Potential Call From HHS - Investor's Business Daily

Mar 19, 2025

Mar 19, 2025

Stock of the Day: Gilead Sciences falls on report the Trump administration could slash funds for HIV prevention - Yahoo Finance

Mar 19, 2025

Mar 19, 2025

Wall Street weighs in on Gilead as shares fall on possible U.S. HIV cuts - Investing.com Canada

Mar 19, 2025

Mar 19, 2025

BMO reiterates Gilead stock with $115 target amid HIV funding concerns - Investing.com

Mar 19, 2025

Mar 19, 2025

Citi maintains Gilead stock Buy rating, $125 target amid HIV funding fears - Investing.com

Mar 19, 2025

Mar 19, 2025

Gilead Sciences Should Not See Any Impact From HIV-Related Cost Reductions at US Healthcare Department, Truist Says - Marketscreener.com

Mar 19, 2025

Mar 19, 2025

Gilead Sciences Ranked in Top Five Most JUST List for Biopharma Companies - CSRwire.com

Mar 19, 2025

Mar 19, 2025

Gilead Sciences’ SWOT analysis: HIV giant’s stock faces pivotal transition - Investing.com

Mar 19, 2025

Mar 19, 2025

Gilead Sciences Stock Slips on Possible HIV Funding Cut - Schaeffers Research

Mar 19, 2025

Mar 19, 2025

Why Gilead Sciences (GILD) Is Among the Most Undervalued Biotech Stocks to Invest In - Insider Monkey

Mar 19, 2025

Mar 19, 2025

Citi Defending Gilead Sciences (GILD): 'we are buyers of GILD stock on any weakness ahead of the upcoming Len PrEP launch in mid-2025' - StreetInsider.com

Mar 19, 2025

Mar 19, 2025

Gilead Stock Falls on Report Trump Administration Wants to Cut HIV-Prevention Funding - Barron's

Mar 19, 2025

Mar 19, 2025

Gilead Stock (NYSE:GILD) Slumps on HIV Funding Cuts Report - TipRanks

Mar 19, 2025

Mar 19, 2025

Gilead slides as Trump administration puts HIV prevention funds under review - TradingView

Mar 19, 2025

Mar 19, 2025

Gilead Sciences (GILD): Potential Impact of Federal HIV Funding Cuts - Value the Markets

Mar 19, 2025